亚盛医药啃下“硬骨头”,百亿Bcl-2药物市场格局生变

21世纪经济报道
Jul 18

一款中国原创药物,打破了跨国药企近十年的垄断,彻底改写了全球抗癌药市场的竞争格局。  近日,创新药企亚盛医药(纳斯达克代码:AAPG;香港联交所代码:6855)宣布,公司自主研发的新型Bcl-2选择性抑制剂利生妥®(通用名:利沙托克拉;研发代码:APG-2575)获中国国家药品监督管理局(NMPA)批准附条件上市。该药物适用于既往经过至少包含布鲁顿酪氨酸激酶(BTK)抑制剂在内的一种系统治疗的成人...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10